Journal article
A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer
Abstract
INTRODUCTION: BI 2536 is a potent, highly selective inhibitor of polo-like kinase (Plk) 1. This open-label, phase I study investigated the maximum tolerated dose (MTD), safety, efficacy, and pharmacokinetics (PK) of BI 2536 IV in combination with standard-dose pemetrexed in previously treated advanced or metastatic non-small-cell lung cancer.
PATIENTS AND METHODS: A standard 3 + 3 design was used. The patients received 500 mg/m(2) pemetrexed …
Authors
Ellis PM; Chu QS; Leighl N; Laurie SA; Fritsch H; Gaschler-Markefski B; Gyorffy S; Munzert G
Journal
Clinical Lung Cancer, Vol. 14, No. 1, pp. 19–27
Publisher
Elsevier
Publication Date
January 2013
DOI
10.1016/j.cllc.2012.04.003
ISSN
1525-7304
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, IntravenousAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCell Cycle ProteinsDisease-Free SurvivalDrug EruptionsDrug InteractionsEnzyme InhibitorsFatigueFemaleGlutamatesGuanineHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedNauseaNeutropeniaPemetrexedProtein Serine-Threonine KinasesProto-Oncogene ProteinsPruritusPteridinesTreatment OutcomePolo-Like Kinase 1